Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALID: Dual RAS Blockade in Type 2 Diabetic Nephropathy
NCT00494715Phase 3Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- May 2007
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of benazepril and valsartan in diabetic nephropathy (DN) (3 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Progression to End Stage Renal Disease at 3 years. Started May 2007; status: completed.
02
Drugs
benazeprilvalsartan
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT00494715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00494715.